Pharmacyclics Inc. (PCYC)
-NasdaqCM 77.87 
1.62(2.12%) 4:00PM EDT|After Hours
:
77.89 0.02 (0.02%) 4:45PM EDT
| Prev Close: | 76.25 |
|---|
| Open: | 77.35 |
|---|
| Bid: | 77.00 x 500 |
|---|
| Ask: | 91.25 x 100 |
|---|
| 1y Target Est: | 98.20 |
|---|
| Beta: | 0.96 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 75.50 - 78.79 |
|---|
| 52wk Range: | 26.23 - 95.85 |
|---|
| Volume: | 590,792 |
|---|
| Avg Vol (3m): | 792,589 |
|---|
| Market Cap: | 5.49B |
|---|
| P/E (ttm): | 65.88 |
|---|
| EPS (ttm): | 1.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Wider-Than-Expected Loss at PharmacyclicsZacks(Thu 1:30PM EDT)
- David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in GenericsWall Street Transcript(Thu 11:08AM EDT)
- Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Pharmacyclics Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 1)
- Pharmacyclics posts bigger 1Q loss on stock costsAP(Wed, May 1)
- Can This Biotech Soar Again?at Motley Fool(Wed, May 1)
- Pharmacyclics Reports First Quarter 2013 ResultsPR Newswire(Wed, May 1)
- PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitEDGAR Online(Wed, May 1)
- Q3 2013 Pharmacyclics Earnings Release - After Market CloseCCBN(Wed, May 1)
- Tracking Cash Inflows: A Good Method to Locate Investment Opportunitiesat Motley Fool(Sun, Apr 28)
- Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Apr 26)
- FDA Designation for Merck CandidateZacks(Thu, Apr 25)
- Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference CallPR Newswire(Wed, Apr 24)
- Abbott - Epizyme CollaborateZacks(Tue, Apr 23)
- Pharmacyclics Larger Than S&P 500 Component Interpublic Group of Companiesat Forbes(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | 778.70 |
|---|
| P/S (ttm): | 32.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.09 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.17 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -5,619.44 |
|---|
Business Summary
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.
View More